Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Net Income (2016 - 2025)

Historic Net Income for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to -$31.2 million.

  • Sanara MedTech's Net Income fell 105618.36% to -$31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.5 million, marking a year-over-year decrease of 42411.28%. This contributed to the annual value of -$9.8 million for FY2024, which is 12121.86% down from last year.
  • According to the latest figures from Q3 2025, Sanara MedTech's Net Income is -$31.2 million, which was down 105618.36% from -$1.8 million recorded in Q2 2025.
  • Sanara MedTech's 5-year Net Income high stood at $756914.0 for Q2 2022, and its period low was -$31.2 million during Q3 2025.
  • For the 5-year period, Sanara MedTech's Net Income averaged around -$3.8 million, with its median value being -$1.9 million (2023).
  • Per our database at Business Quant, Sanara MedTech's Net Income skyrocketed by 17375.86% in 2022 and then plummeted by 256839.06% in 2024.
  • Sanara MedTech's Net Income (Quarter) stood at -$3.6 million in 2021, then fell by 17.06% to -$4.2 million in 2022, then soared by 93.7% to -$262444.0 in 2023, then plummeted by 2568.39% to -$7.0 million in 2024, then crashed by 346.19% to -$31.2 million in 2025.
  • Its Net Income was -$31.2 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$3.4 million in Q1 2025.